ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0857

Exploring Clinical Outcomes of Patients with Cardiac Sarcoidosis on TNF Inhibitors: A Nationwide Retrospective Cohort Study
Abstract Number: 1231

Exploring Long-term Complications of Lyme Disease – Insights from a Retrospective Cohort Study
Abstract Number: 1096

Exploring Multi Factorial Model for the Prediction of Gout in Patients with Hyperuricemia
Abstract Number: 1725

Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Abstract Number: 2100

Exploring the Association Between Basketball Participation and Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 1579

Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis
Abstract Number: 1918

Exploring the Childhood Opportunity Index and Distance to Care in a Cohort of Children with Rheumatic Disease
Abstract Number: 0429

Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Abstract Number: 0785

Exploring the Link Between Atgl-Dependent Lipolysis and Dermal Fibrosis in Systemic Sclerosis
Abstract Number: 0276

Exploring the Prevalence of Crowned Dens Syndrome in a Polymyalgia Rheumatica Veterans Affairs Patient Cohort
Abstract Number: 1374

Exploring Two Decades of Therapeutic Challenges: A Monocentric Experience in Rheumatoid Arthritis Patients Battling Cancer
Abstract Number: 2639

Exploring Weight Trends in Psoriatic Arthritis: Unraveling Effects of Drugs
Abstract Number: 1847

Expression Levels of the ATP-Gated Ion Channel P2RX7 Do Not Predict T Cell Sensitivity to Extracellular ATP and NAD
Abstract Number: 1675

Extended Validation of the IgG4-Related Disease Symptom Severity Index (SSI)
Abstract Number: 2650

Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Complications in Giant Cell Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].